KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Retained Earnings (2016 - 2026)

Gsk has reported Retained Earnings over the past 18 years, most recently at $15.6 billion for Q1 2026.

  • For Q1 2026, Retained Earnings rose 49.34% year-over-year to $15.6 billion; the TTM value through Mar 2026 reached $15.6 billion, up 49.34%, while the annual FY2025 figure was $13.6 billion, 35.71% up from the prior year.
  • Retained Earnings for Q1 2026 was $15.6 billion at Gsk, up from $13.6 billion in the prior quarter.
  • Over five years, Retained Earnings peaked at $15.6 billion in Q1 2026 and troughed at $1.7 billion in Q4 2022.
  • A 5-year average of $9.6 billion and a median of $10.5 billion in 2025 define the central range for Retained Earnings.
  • Biggest five-year swings in Retained Earnings: crashed 71.53% in 2022 and later surged 278.68% in 2024.
  • Year by year, Retained Earnings stood at $1.7 billion in 2022, then surged by 55.58% to $2.6 billion in 2023, then surged by 278.68% to $10.0 billion in 2024, then skyrocketed by 35.71% to $13.6 billion in 2025, then increased by 15.06% to $15.6 billion in 2026.
  • Business Quant data shows Retained Earnings for GSK at $15.6 billion in Q1 2026, $13.6 billion in Q4 2025, and $13.5 billion in Q3 2025.